

From: "Solow, Sara (ODAG)" (b) (6)

To: "Henthorne, Betsy (OASG)" <(b) (6)>

Subject: RE: Safe Injection Sites

Date: Mon, 2 May 2022 14:20:50 +0000

Importance: Normal

Sounds good, some quick feedback below in red.

Sara A. Solow
Senior Counsel
Office of the Deputy Attorney General
U.S. Department of Justice
Cell: (b) (6)
Other: (b) (6)

From: Henthorne, Betsy (OASG) <(b) (6)>

Sent: Sunday, May 1, 2022 10:22 PM

To: Solow, Sara (ODAG) (b) (6)

Subject: RE: Safe Injection Sites

Sorry I didn't get a chance to respond Friday—an absolutely insane day. Responses below in blue!

From: Solow, Sara (ODAG) (b) (6)

Sent: Friday, April 29, 2022 11:09 AM

To: Henthorne, Betsy (OASG) <(b) (6)>

Subject: RE: Safe Injection Sites

Oh ok nice – I did not know if you guys were still working on that document or had moved beyond it. So a few things:

--On the memo/process/next steps: (b) (5)

(I have been asked to give an update to the DAG on where things stand/our process.). I am happy to help edit the options memo as well, of course.

Options memo is with Matthew now. I know he wants Vanita to see it as well and of course we will want you to review and weigh in. I'll touch base with you on timing for that tomorrow, but we talked about getting it to the DAG early this week if possible. (b) (5)

but will let you know if Matthew wants to change that. Understood. I strongly advise (b) (5)

--On the Rhode Island MOU – after CIV comes back to us mid-Monday, would you like me to take first cut at accepting/incorporating edits from both then and NDDS, and flip back to you guys, or visa versa?

Would love for you to take a first cut at reconciling the CIV/NDDS edits to the MOU, if you're able. Will do. For the version that goes onwards, we may have to include something like, (b) (5)

--On Philly, (b) (5)

[REDACTED]

Let's ask for any additional comments or redlines by mid-day Wednesday.

--On the Rhode Island letter -- (b) (5)

[REDACTED]

is there anyone you could ask to take a first cut?

No one comes immediately to mind, but will think about it and we can evaluate once we have a cleaner draft of the MOU (at which point I think it will be clearer what needs to be added/changed in a letter). We don't have an intern available right now unfortunately.

Yours
Sara

Sara A. Solow
Senior Counsel
Office of the Deputy Attorney General
U.S. Department of Justice
Cell: (b) (6)
Other: (b) (6)

From: Henthorne, Betsy (OASG) <(b) (6)>

Sent: Friday, April 29, 2022 12:42 AM

To: Solow, Sara (ODAG) (b) (6)

Subject: RE: Safe Injection Sites

I have been working on (b) (6) and will now incorporate the more recent feedback and get a full draft finalized, likely over the weekend.

I think it will probably make sense to see what it looks like as (b) (6)

[REDACTED] It seems like (b) (6) are both viable options and it might be really helpful to see what the same basic content looks like in the two different forms.

From: Solow, Sara (ODAG) (b) (6)

Sent: Friday, April 29, 2022 12:39 AM

To: Henthorne, Betsy (OASG) <(b) (6)>

Subject: Re: Safe Injection Sites

Gotcha.

So what are you and Matthew thinking in terms of next steps as the feedback rolls in on the RI thing - (b) (5)

Just trying to figure out how we will be aiming to move this onwards ...

I think I am personally still in the camp of (b) (5). But happy to discuss, as I see arguments in favor of 2b.

Sara

Sent from my iPhone

On Apr 28, 2022, at 10:38 PM, Henthorne, Betsy (OASG) <(b) (6)> wrote:

Also I think (b) (5)

From: Solow, Sara (ODAG) (b) (6)

Sent: Thursday, April 28, 2022 11:18 AM

To: Henthorne, Betsy (OASG) <(b) (6)> Colangelo, Matthew (OASG)

(b) (6) Folk, Anders (ODAG) (b) (6)

Subject: FW: Safe Injection Sites

Hi both,

I think we should ask them to please make any recommended edits to the draft MOU to address the points I highlighted in yellow -- clarifying the (b) (5), as well as the (b) (5), in the ways they think could be beneficial.

On the sentence I highlighted in red, and their general proclivity (from how I read this) towards (b) (6), we can convey that suggestion onwards, but I do not really agree with either basis for supporting it. They said it might be viewed as (b) (6)

But to the contrary, I think (b) (6)

They also say that an (b) (6)

But that is not correct; (b) (6)

(b) (6), in my view, (b) (6)

(One thing: (b) (6)

So as for next steps, (b) (6)

Or should we talk about that first?

Sara

Sara A. Solow
Senior Counsel
Office of the Deputy Attorney General
U.S. Department of Justice
Cell: (b) (6)
Other: (b) (6)

From: Netter, Brian (CIV) (b) (6)
Sent: Wednesday, April 27, 2022 11:37 PM
To: Henthorne, Betsy (OASG) <(b) (6)>
Cc: Boynton, Brian M. (CIV) (b) (6); Colangelo, Matthew (OASG)
(b) (6); Solow, Sara (ODAG) (b) (6)
Subject: Re: Safe Injection Sites

Duplicative

From: "Henthorne, Betsy (OASG)" <(b) (6)>

To: "Colangelo, Matthew (OASG)" (b) (6)

Subject: FW: Safe consumption sites - draft MOU

Date: Fri, 29 Apr 2022 04:44:20 +0000

Importance: Normal

Attachments: Draft_MOU_w-RI_SCS_for_discussion_NDDS-ed_Shared-28-Apr-2022-eve.docx

I will incorporate this feedback and what we got from CIV into the memo and send you a full draft over the weekend, if that works?

Once we have CIV's redlines to the MOU doc, it seems worthwhile to (b) (5)

Thoughts?

From: Matz, Harry (CRM) (b) (6)

Sent: Thursday, April 28, 2022 6:53 PM

To: Solow, Sara (ODAG) (b) (6); Hodge, Jennifer (CRM) (b) (6); Wyatt, Arthur (CRM) (b) (6); Watkins, Lena (CRM) (b) (6)

Cc: Henthorne, Betsy (OASG) <(b) (6)> Colangelo, Matthew (OASG)

(b) (6)

Subject: RE: Safe consumption sites - draft MOU

Duplicative

From: "Colangelo, Matthew (OASG)" (b) (6)

To: "Henthorne, Betsy (OASG)" <(b) (6)> "Solow, Sara (ODAG)"
(b) (6), "Folk, Anders (ODAG)" (b) (6)

Subject: RE: Safe Injection Sites

Date: Thu, 28 Apr 2022 19:03:24 +0000

Importance: Normal

no concerns here, thank you

From: Henthorne, Betsy (OASG) <(b) (6)>

Sent: Thursday, April 28, 2022 2:51 PM

To: Solow, Sara (ODAG) <(b) (6)> Colangelo, Matthew (OASG) (b) (6);
Folk, Anders (ODAG) (b) (6)

Subject: RE: Safe Injection Sites

I had the same thought re the redline. Matthew, unless you'd prefer holding off, I can ask Brian to go ahead and do that.

I also agree I didn't find (b) (5).

Sara, have you gotten anything back from NDDS? If not, can you ping them? Thanks!

From: Solow, Sara (ODAG) <(b) (6)>

Sent: Thursday, April 28, 2022 11:18 AM

To: Henthorne, Betsy (OASG) <(b) (6)> Colangelo, Matthew (OASG)
(b) (6); Folk, Anders (ODAG) (b) (6)

Subject: FW: Safe Injection Sites

Duplicative